This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.
Heart Failure Hospital Quality of Life 
HCPLive
AUGUST 31, 2024
RESHAPE-HF2 shows mitral transcatheter edge-to-edge repair (M-TEER) reduces heart failure hospitalizations and improves quality of life vs optimal medical therapy alone.
DAIC
JULY 25, 2024
BioCardia previously confirmed alignment with the United States Food and Drug Administration (FDA) on the design of the 250-patient randomized, controlled trial and the minimum of 12-month primary composite endpoint of all cause death, reduction in major adverse cardiovascular events, and improvement in quality of life.
111 
HCPLive
MARCH 14, 2024
The AccuCinch® System, utilized by Allegheny General Hospital, offers a breakthrough approach to treating heart failure by targeting the left ventricle.
American College of Cardiology
AUGUST 2, 2024
Iron deficiency (ID) is a common comorbidity among patients with heart failure (HF), and it is associated with reduced exercise tolerance and quality of life and serves as a marker of increased risk of hospitalizations and mortality.
Becker's Hospital Review - Cardiology
JULY 9, 2024
New study finds strict sodium restrictions may not benefit heart failure patients. per day can improve quality of life Moderate salt intake of 3.0-4.5g
DAIC
FEBRUARY 21, 2024
Getty Images milla1cf Wed, 02/21/2024 - 19:10 February 21, 2024 — Ochsner Children's Hospital , ranked among the top hospitals in the nation for pediatric cardiology and congenital heart surgery, is raising awareness of the need for more pediatric-specific heart devices.
105 
DAIC
MARCH 13, 2024
CMS has reviewed the CardiAMP Heart Failure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage. The CardiAMP Heart Failure II Trial is FDA approved to enroll up to 250 patients at up to 40 clinical centers. said Peter Altman , PhD.,
111 
European Journal of Heart Failure
NOVEMBER 29, 2023
ABSTRACT Aims Heart failure outcomes remain poor despite advances in therapy. The European Society of Cardiology Heart Failure III Registry (ESC HF III Registry) aims to characterize HF clinical features and outcomes and to assess implementation of guideline-recommended therapy in Europe and other ESC affiliated countries.
European Journal of Heart Failure
DECEMBER 22, 2023
Abstract Right-sided heart failure and tricuspid regurgitation are common and strongly associated with poor quality of life and an increased risk of heart failure hospitalizations and death. This article is protected by copyright. All rights reserved.
DAIC
MAY 28, 2024
milla1cf Tue, 05/28/2024 - 07:00 May 28, 2024 — Yoga focused on breathing, meditation, and relaxation is linked with symptom improvement in patients with heart failure, according to research presented at Heart Failure 2024 , a scientific congress of the European Society of Cardiology (ESC).
European Journal of Heart Failure
DECEMBER 13, 2023
ABSTRACT Aim Chronic obstructive pulmonary disease (COPD) is common in heart failure with a mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) and is associated with worse outcomes. The primary outcome was a composite of cardiovascular death or worsening heart failure. 0.93]; COPD: HR 0.82 [95% CI 0.62–1.10];
Circulation: Heart Failure
MARCH 5, 2024
Circulation: Heart Failure, Ahead of Print. The strongest independent predictors of a greater improvement in QoL were younger age (P<0.001), no HF hospitalization in the previous year (P<0.001), lower NYHA class before hospital admission (P<0.001) and high-intensity care treatment (mean difference, 4.2 [95%
Open Heart
AUGUST 10, 2023
Background Atrial fibrillation (AF) is common in individuals with heart failure (HF). Individuals with HF and AF may have a reduced functional capacity and quality of life (QoL) which leads to hospital admission and burden on clinical services. Results 149 individuals were propensity matched from each group.
European Journal of Heart Failure
OCTOBER 31, 2023
This 2023 Cochrane review of 60 randomized trials in 8728 heart failure patients, confirms the benefits of participation in exercise-based cardiac rehabilitation (ExCR), including reduced risk of hospitalization and a clinically meaningful improvement in health-related quality of life.
DAIC
APRIL 9, 2024
Decline in exercise ability is a hallmark of progression to overt heart failure. These results also speak to the importance of continuing to focus on earlier recognition of heart failure risk in patients with diabetes and on initiating treatment before the condition has progressed to overt heart failure.”
HeartRhythm
MAY 29, 2024
Current guidelines recommend ICD implantation in individuals with symptomatic heart failure (HF) and reduced left ventricular ejection fraction (HFrEF) if they have been receiving optimal guideline directed medical therapy for at least 3-6 months and who are expected to have survival greater than one year with meaningful quality of life (1).
Open Heart
JULY 11, 2022
Background Electrical muscle stimulation (EMS) is being evaluated as a possible alternative to exercise training to improve functional capacity in severely deconditioned patients with heart failure (HF). However, there is insufficient data on delayed effects of EMS starting early after decompensation.
DAIC
APRIL 16, 2024
a commercial-stage medical device company, announced today the availability of additional data, including the publication of results of the post-market phase of the BeAT-HF trial in the European Journal of Heart Failure. The manuscript is available online at the European Journal of Heart Failure website.
104 
Dr. Sanjay Gupta
MAY 23, 2022
Today’s vlog is on the subject of heart failure and in particular on a special type of pacemaker which can make a significant improvement to the quality of life and length of life in patients with heart failure. What is heart failure?
HeartRhythm
MAY 2, 2024
Rhythm control with either medications or catheter ablation is an established strategy for symptomatic patients with atrial fibrillation (AF), by reducing arrhythmic burden and improving patient quality of life, as well as reducing the risk of heart failure hospitalization and mortality in select populations with concomitant AF and heart failure.
European Journal of Heart Failure
OCTOBER 4, 2023
CI, confidence interval; COPD, chronic obstructive pulmonary disease; HF, heart failure; HR, hazard ratio; TIA, transient ischaemic attack. The treatment effect of HIC versus UC on the primary endpoint, 180-day death or heart failure (HF) rehospitalization, was compared by NCC number and by each individual comorbidity.
Open Heart
JANUARY 18, 2024
Background Heart failure (HF) remains a major public health problem with a high mortality and morbidity worldwide. The primary endpoint assessed the key safety outcomes, the secondary endpoints were: the quality of life measured, the N-terminal pro-B-type natriuretic peptide (NT-proBNP) changes and 6 min walk test (6MWT).
DAIC
FEBRUARY 2, 2024
“Patients suffering with tricuspid regurgitation endure life-impairing symptoms and, until today, had no approved transcatheter treatment options,” said Susheel Kodali, MD , director, Structural Heart and Valve Center at Columbia University Irving Medical Center/New York-Presbyterian Hospital and TRISCEND II Study Principal Investigator.
100 
HeartRhythm
SEPTEMBER 20, 2023
1 CSP offers an elegant treatment solution to the challenging problem of heart failure (HF) caused by electrical dyssynchrony due to left bundle branch block (LBBB). Cardiac resynchronization therapy improves survival and quality of life and reduces HF hospitalizations in HF patients with LBBB.1
DAIC
MAY 14, 2024
In about 70 percent of cases, patients with HCM experience obstruction to blood flow, which increases pressures in the heart and can lead to chest pain, shortness of breath and reduced exercise capacity. The late breaking research was presented by principal investigator Martin S. Cytokinetics Inc. provided the funding for this study.
126 
DAIC
APRIL 2, 2024
Food and Drug Administration (FDA) approval of its TriClip, a first-of-its-kind device to repair leaky tricuspid heart valve, for which more than 1.6 are affected by tricuspid regurgitation, 1 which can severely impact quality of life. Abbott has announced U.S million people in the U.S. are estimated to be affected. and Lynn C.
105 
DAIC
JANUARY 16, 2024
He led the structural heart program and cardiac catheterization laboratory at the University of Cincinnati and spent several years with The Christ Hospital in Ohio. There, he served as an investigator in many high-profile clinical trials, including several significant structural heart studies.
Journal of Cardiovascular Electrophysiology
NOVEMBER 27, 2023
Abstract Continuous flow left ventricular assist devices (CF-LVADs) have been shown to reduce mortality and morbidity in patients with advanced heart failure with reduced ejection fraction.
DAIC
FEBRUARY 12, 2024
A team at Allina Health’s Abbott Northwestern Hospital has successfully completed the first Barostim Baroreflex Activation Therapy implant in the state of Minnesota, according to an announcement from CVRx, Inc. I felt weak and tired all the time and knew I didn’t want to spend my life sitting in the living room chair.
104 
DAIC
APRIL 9, 2024
Maron, MD “Our findings provide enthusiasm that a novel drug therapy with ninerafaxstat may provide nonobstructive HCM patients an opportunity to achieve a better quality of life by decreasing symptom burden and improving exercise capacity,” said Martin S. The safety and tolerability of the drug in this phase 2 trial was excellent.
Circulation: Cardiovascular Quality & Outcomes
NOVEMBER 6, 2023
The REVIVED-BCIS2 trial concluded that PCI did not reduce the incidence of all-cause death or heart failure (HF) hospitalization, however patients assigned to PCI reported better initial health-related quality of life than those assigned to optimal medical therapy (OMT) alone.
DAIC
APRIL 9, 2024
UC Davis Medical Center is one of the first sites nationwide to have commercial access to TriClip and is the first hospital in Western United States to utilize the system since it was approved by the U.S. Left untreated, tricuspid regurgitation can lead to atrial fibrillation , heart failure , kidney disease and even death.
111 
All About Cardiovascular System and Disorders
OCTOBER 25, 2023
AF-CHF trial in those with AF and congestive heart failure also failed to show any advantage for the rhythm control strategy [3]. Overall, it appears that rhythm control strategy in AF may be better in those with heart failure and in those with associated cardiovascular conditions and early AF.
DAIC
APRIL 9, 2024
Compared to their peers without the condition, people with atrial fibrillation are twice as likely to be admitted to hospital, five times more likely to have a stroke, three times more likely to develop heart failure, and twice as likely to die prematurely.4
DAIC
APRIL 6, 2024
The trial, called RELIEVE-HF , is the first randomized placebo-procedure controlled trial of interatrial shunting that included patients with both major types of heart failure : heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF).
DAIC
APRIL 6, 2024
The trial, called RELIEVE-HF , is the first randomized placebo-procedure controlled trial of interatrial shunting that included patients with both major types of heart failure : heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF).
DAIC
FEBRUARY 12, 2024
A team at Allina Health Minneapolis Heart Institute at Abbott Northwestern Hospital has successfully completed the first Barostim Baroreflex Activation Therapy implant in the state of Minnesota, according to an announcement from CVRx, Inc. and Allina Health. and Allina Health. and Allina Health.
DAIC
APRIL 9, 2024
Bryfogle Professor of Cardiovascular Medicine at the Perelman School of Medicine at the University of Pennsylvania, section chief for interventional cardiology at the Hospital of the University of Pennsylvania and the study’s lead author. Herrmann, MD , John W. There was a huge difference— 32.2 of those receiving the SAPIEN valve.
59 
The Beat Blog
MAY 2, 2023
I’ve worked with hospitals, provider groups and payers – trying to help drive the right type of access, care, and value across the healthcare continuum. One of the biggest challenges I’ve observed is access to high-quality and timely rural healthcare. Throughout my career, I’ve witnessed a lot of changes in healthcare.
DAIC
MARCH 29, 2024
The primary effectiveness endpoint was a composite of death, heart transplant/left ventricular assist device (LVAD) implantation, HF hospitalization, outpatient HF worsening, and quality of life. where it is a leading cause of death and hospitalization, i and 56.2 and worldwide," said Neal Eigler, M.D. ,
CardiacWire
AUGUST 2, 2024
Lilly’s blockbuster GLP-1 tirzepatide appears poised to become the next major HFpEF drug, after topline results from the SUMMIT trial showed that it significantly improved both outcomes and symptoms among patients with heart failure with preserved ejection fraction and obesity. vs. +15 KCCQ-CSS points). vs. -2.2%).
59 
Society of Thoracic Surgeons - Research
APRIL 20, 2023
Program Designations Access and Publications (A&P) 1 Participant User File (PUF) 2 Task Force on Funded Research (TFR) 3 Special Projects 4 Adult Cardiac Surgery Database Lead Author Title Publication Date William Keeling 2 National Trends in Emergency Coronary Artery Bypass Grafting European Journal of Cardiothoracic Surgery October 2023 Jake (..)
52 
Society of Thoracic Surgeons - Research
APRIL 20, 2023
Adult Cardiac Surgery Database Lead Author Title Publication Date Jacob Raphael Red Blood Cell Transfusion and Pulmonary Complications: The Society of Thoracic Surgeons Adult Cardiac Surgery Database Analysis The Annals of Thoracic Surgery January 2024 Joseph Sabik Multi-Arterial versus Single-Arterial Coronary Surgery: Ten Year Follow-up of One Million (..)
52
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content